Barclays PLC Makes New Investment in Clover Health Investments, Corp. (NASDAQ:CLOV)

Barclays PLC acquired a new position in Clover Health Investments, Corp. (NASDAQ:CLOV) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 105,766 shares of the company’s stock, valued at approximately $298,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp boosted its position in Clover Health Investments by 65.0% in the third quarter. State Street Corp now owns 2,189,380 shares of the company’s stock worth $6,174,000 after purchasing an additional 862,621 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Clover Health Investments during the 3rd quarter valued at $735,000. Parallax Volatility Advisers L.P. purchased a new position in shares of Clover Health Investments during the 3rd quarter valued at $38,000. Janus Henderson Group PLC purchased a new position in shares of Clover Health Investments during the 3rd quarter valued at $477,000. Finally, HighTower Advisors LLC purchased a new position in shares of Clover Health Investments during the 3rd quarter valued at $97,000. Hedge funds and other institutional investors own 19.77% of the company’s stock.

Clover Health Investments Price Performance

Shares of NASDAQ CLOV opened at $3.29 on Monday. Clover Health Investments, Corp. has a one year low of $0.61 and a one year high of $4.71. The business’s fifty day moving average price is $3.42 and its 200-day moving average price is $2.84. The stock has a market capitalization of $1.65 billion, a PE ratio of -16.45 and a beta of 1.95.

Clover Health Investments (NASDAQ:CLOV) last issued its earnings results on Wednesday, November 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. The business had revenue of $330.99 million during the quarter, compared to the consensus estimate of $347.60 million. During the same quarter last year, the company earned ($0.09) EPS. As a group, equities analysts expect that Clover Health Investments, Corp. will post -0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CLOV. Craig Hallum began coverage on Clover Health Investments in a research report on Tuesday, December 17th. They set a “buy” rating and a $6.00 price target on the stock. UBS Group began coverage on Clover Health Investments in a research report on Monday, October 7th. They set a “neutral” rating and a $4.00 price target on the stock.

Clover Health Investments Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.